Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Admilparant (Primary)
  • Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 24 Oct 2023 According to a Bristol-Myers Squibb Media Release, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for BMS-986278 for the treatment of progressive pulmonary fibrosis, based on data from this trial.
  • 24 Oct 2023 According to a Bristol-Myers Squibb Media Release, data from this trial were presented at the European Respiratory Society (ERS) 2023 International Congress in September 2023.
  • 19 Oct 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top